Skip to main content

Carolina Awarded $2.91 Million to Create New Ultra-long-acting HIV Drug Delivery Implant

November 6, 2019

HIV clinical trials have shown that the protective efficacy of daily antiretroviral drugs for the prevention of HIV transmission correlates with adherence – whether an uninfected person takes the prescribed medication at proper times. But nonadherence is a major roadblock toward decreasing the spread of HIV. One solution to the adherence problem is to make drug delivery less frequent but no less effective.